Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade
Ravi B. Patel, Reinier Hernandez, Peter M. Carlson, Joseph J. Grudzinski, Amber M. Bates, Justin C. Jagodinsky, Amy K. Erbe, Ian R. Marsh, Ian S. Arthur, Eduardo Aluicio‐Sarduy, Raghava N. Sriramaneni, Won Jong Jin, Christopher Massey, Alexander L. Rakhmilevich, David M. Vail, Johnathan W. Engle, Trаng Lе, KyungMann Kim, Bryan P. Bednarz, Paul M. Sondel, Jamey P. Weichert, Zachary S. Morris
Abstract
T cells, and reduced metastases. In mice bearing multiple tumors, combining TRT with moderate-dose (12 gray) external beam radiotherapy (EBRT) targeting a single tumor augmented response to ICIs compared to combination of ICIs with either TRT or EBRT alone. The safety of TRT was confirmed in a companion canine study. Low-dose TRT represents a translatable approach to promote response to ICIs for many tumor types, regardless of location.